Sign in with Google
bullish
EuBiologics (206650 KS): Accelerated Double-Digit Sales Growth In 2022; Strong Demand to Continue
323 Views22 Feb 2023 10:51
SUMMARY
- In 2022, Eubiologics (206650 KS) reported revenue growth of 41% YoY to KRW55.47B, driven by increased supply of cholera vaccine to UNICEF following the outbreak of cholera worldwide.
- In 2022, more than 29 countries reported cholera cases or outbreaks, up from 20 countries five year ago. Globally cholera vaccine is in short supply.
- Eubiologic’s vaccine manufacturing capacity is expected to go up to 90 million doses after completion of the expansion project this year, which will drive sustainable sales growth.
Related Insights
More »Loading
Trending Collections
More »Loading
Trending Insights
More »- Zhejiang Sanhua Intelligent Controls (2050 HK): Big Raise Supported by Cornerstones
- Singapore Airlines - Confluence of events (SIA SP, CP SGD7.03, HOLD, TP SGD6.85, Airlines)
- HEW: Geopolitics Blow Hot And Warm
- Key Markets Tactical Outlooks After Israel Strike on Iran
- Wuxi Biologics Placement - Smaller Deal than Previous as Last Didn’t Do Well, Overhang Remain
Top Unpaywalled Insights
More »Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- EuBiologics (206650 KS): Secular Sectoral Tailwind Is Not The Only Catalyst15 Apr 2024
- EuBiologics (206650 KS): Solid 1H23 Performance; Oral Cholera Vaccine on A Consistent Growth Path09 Sep 2023
- EuBiologics (206650 KS): Capacity Expansion Amid Global Supply Shortage to Accelerate Growth23 May 2023
- EuBiologics (206650 KS): Base Business Recovery; COVID Vaccine Undergoing Phase 3 Trial18 Mar 2022
- EuBiologics (206650 KS): Cashing on Vaccine Business12 Oct 2021
x